IGF-1 production-promoting agent

Patent metadata

Field	Value
Publication number	US-9801404-B2
Application number	US-201314651423-A
Country	US
Kind code	B2
Filing date	Jun 28, 2013
Priority date	Dec 26, 2012
Publication date	Oct 31, 2017
Grant date	Oct 31, 2017

Abstract

An extract of Citrus depressa , preferably a water and/or organic solvent extract of a fruit of leaf of Citrus depressa , a supercritical extract of a fruit of leaf of Citrus depressa , or a subcritical extract of a fruit of leaf of Citrus depressa , which comprise 0.3 mass % or more of a polymethoxyflavonoid more than in terms of solid matter, for example, an extract of Citrus depressa comprising 0.2 mass % or more of nobiletin and/or 0.1 mass % or more of tangeretin in terms of solid matter, or a polymethoxyflavonoid such as nobiletin or tangeretin is used as an active ingredient of an IGF-1 production-promoting agent.

First claim

What is claimed is:

1. A method for treating a disease by promoting insulin-like growth factor-1 (IGF-1) production in a mammal comprising administering an IGF-1 production-promoting agent to the mammal wherein the agent comprises a polymethoxyflavonoid as an active ingredient, wherein the disease is sarcopenia.

2. The method according to claim 1 , wherein the polymethoxyflavonoid is nobiletin and/or tangeretin.

3. The method according to claim 1 , wherein the polymethoxyflavonoid is contained in an extract of Citrus depressa in an amount of 0.3 mass % or more in terms of solid matter as an active ingredient.

4. The method according to claim 3 , wherein the agent further comprises a clathrating agent to make the polymethoxyflavonoid water-soluble.

5. The method according to claim 4 , wherein the clathrating agent is cyclodextrin, and wherein content thereof is 0.1 to 95 mass % based on the total mass of the solid matter of the extract of Citrus depressa and cyclodextrin.

6. The method according to claim 3 , wherein the extract of Citrus depressa comprises 0.2 mass % or more of nobiletin, and/or 0.1 mass % or more of tangeretin in terms of solid matter as an active ingredient.

7. The method according to claim 1 , resulting in promotion of protein synthesis.

Assignees

• Morinaga Milk Industry Co Ltd

Inventors

• Oshio Kazutaka
• Nakamura Hirohiko
• Sakata Yasuyuki

Classifications

• A61P5/10

  of the posterior pituitary hormones, e.g. oxytocin, ADH · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P21/06

  Anabolic agents (androgens A61P5/26) · CPC title

• A61P1/16

  for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics · CPC title